AcelRx Pharmaceuticals, Inc. (ACRX) Director Mark G. Edwards Purchases 30,000 Shares of Stock

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Director Mark G. Edwards purchased 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average cost of $1.90 per share, with a total value of $57,000.00. Following the completion of the acquisition, the director now directly owns 150,000 shares in the company, valued at $285,000. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

AcelRx Pharmaceuticals, Inc. (ACRX) traded up $0.03 during mid-day trading on Friday, reaching $2.08. The company had a trading volume of 687,124 shares, compared to its average volume of 1,004,681. AcelRx Pharmaceuticals, Inc. has a 12-month low of $1.55 and a 12-month high of $5.75. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43.

COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals, Inc. (ACRX) Director Mark G. Edwards Purchases 30,000 Shares of Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/11/18/acelrx-pharmaceuticals-inc-acrx-director-mark-g-edwards-purchases-30000-shares-of-stock.html.

A number of equities research analysts recently weighed in on ACRX shares. ValuEngine raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Piper Jaffray Companies set a $3.00 price target on AcelRx Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, July 25th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. Roth Capital set a $13.00 price target on AcelRx Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, Zacks Investment Research raised AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $6.83.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geller Family Office Services LLC acquired a new stake in shares of AcelRx Pharmaceuticals in the 3rd quarter valued at $460,000. Perennial Advisors LLC acquired a new stake in shares of AcelRx Pharmaceuticals in the 3rd quarter valued at $138,000. Goldman Sachs Group Inc. acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at $530,000. Virtu KCG Holdings LLC increased its stake in shares of AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. Finally, LMR Partners LLP acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter valued at $319,000. 23.09% of the stock is owned by institutional investors.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Insider Buying and Selling by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply